Clinical Trial

Gait Adaptability in Persons With MS Having Mild Disability

Recruiting
View on ClinicalTrials.gov →
Summary
Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system that frequently leads to walking impairment, balance deficits, fatigue, cognitive difficulties, and an increased risk of falls. Importantly, these problems can already be present in the early stages of the disease and may not be adequately captured by standard clinical walking tests, which primarily assess speed or distance. Such tests are often insufficient to reflect the complexity of real-life walking, which requires continuous adaptation to environmental challenges, and attention to internal and external stimuli. Gait adaptability, the ability to modify walking patterns in response to changing and unpredictable demands such as obstacles or sudden perturbations, is critical for safe mobility and fall prevention. Both proactive (anticipatory) and reactive (feedback-driven) gait adaptations are essential for maintaining balance and functional independence. However, gait adaptability and its underlying neural mechanisms remain insufficiently understood in people with MS. This study aims to provide a comprehensive assessment of gait adaptability in people with MS by evaluating both proactive and reactive gait adaptations using objective gait measurements and cortical activity recordings. The findings may contribute to the development of more sensitive outcome measures and inform targeted rehabilitation strategies that better reflect real-life mobility demands. Primary aims: • To investigate the behavioral measures and neural correlates of reactive and proactive gait adaptability in pwMS compared to HC Secondary aims: * To investigate factors related to gait adaptability * To investigate changes in gait adaptability during prolonged walking conditions
Trial Details
NCT Number NCT07580820
Lead Sponsor Hasselt University
Conditions Multiple Sclerosis, Healthy Adults
Enrollment 32 participants
Start Date 2025-12-05
Primary Completion 2026-09-01 (estimated)
Study Completion 2026-12-20 (estimated)
Updated on ClinicalTrials.gov 2026-05-12